2010 [36] • ≥65 years • Pharmacists trained by investigators • Ads in local newspaper Control 133 • Usual care

and print material from OP Canada RCTc, Canada (Alberta) • 50–64 years with ≥1 major risk factord   • Notices in participating pharmacies Intervention 129 • 30-min appointment on clinic day: 15 community pharmacies • No BMD test in prior 2 years   • Participants called to book appointment      • Print material from OP Canada   • No current OP treatment   • Pharmacist identification in pharmacy      • Pamphlet designed by study investigators   • English speaking          • Pharmacist counseling (tailored OP education)              • Heel QUS measurement and interpretation       LY3039478        • Patients encouraged to follow-up with their primary care physician        

     • Physicians provided with study details, QUS results, Salubrinal and information regarding patient eligibility for central BMD testing              • Follow-up              • Telephone: 2 and 8 weeks              • Patients asked to return to pharmacy at 16 weeks RCT randomized controlled trial (in cluster RCT, PRN1371 cost groups randomized by pharmacy), BMD bone mineral density, DXA dual-energy X-ray absorptiometry, OP osteoporosis, QUS quantitative ultrasound, n number of participants aOf all pharmacists agreeing and eligible to participate, one was randomly selected from each of six suburban and six rural areas. These 12 pharmacists were then randomized into one of two groups with three suburban and three rural pharmacies in each of the two groups bPharmacies from a specialized provider network consisting of pharmacists with previous training and/or certification in drug

therapy monitory and research Neratinib chemical structure participation cRandomized by secure internet randomization services (sequence stratified by site with block size of 4) dMajor risk factor included: family history of osteoporosis, previous fracture, systemic glucocorticoids >3 months, or early menopause eSample size after exclusion of missing data or participants who did not complete the study Table 2 Summary of potential risk of bias based on threats to internal validity Study Selection Bias Information Bias Allocationa Attritionb Performancec Detectiond Crockett et al. [34] High High High High • Better recruitment success in BMD group in rural regions (n = 60 vs. n = 43) • 3-month follow-up, 87% • Definition of risk differed between groups • Self-report assessment based on patient recall of pharmacist recommendations and whether or not they complied with the pharmacist’s recommendations • Non-BMD group had larger proportion with history of low-trauma fracture (21% vs. 11%) • 6-month follow-up, 10%; only “high-risk” followed • Group 1: questionnaire only • Group 2: questionnaire and forearm BMD results McDonough et al.